The markets traded mixed during the midday with the Dow falling 42 points to 16,415 over earnings news. Nasdaq gained 22 points to 4219.
On the upside
ThermoGenesis (Nasdaq: KOOL) and TotipotentRX reported positive results from a Phase Ib clinical trial for its critical limb ischemia treatment CLIRST.
TheStreet identified Cell Therapeutics (Nasdaq: CTIC) as one of the best performing biotechnology stocks of the year.
Raymond James upgraded Inteliquent (Nasdaq: IQNT) from a Market Perform rating to an Outperform rating.
On the downside
Investors locked in profits on Galena Biopharma (Nasdaq: GALE).
Telstra will deploy the Infinera Intelligent Transport Network (Nasdaq: INFN) across multiple ultra-long haul submarine cable routes in Asia Pacific but the stock price fell.
Shares of Cliffs Natural Resources (Nasdaq: CLF) and Vale (NYSE: VALE) fell after Goldman Sachs forecast lower copper and iron ore prices.
In the broad market, advancing issues outpaced decliners by a margin of more than 5 to 3 on the NYSE and by more than 7 to 5 on Nasdaq. The broader S&P 500 added 4 points to 1843. Bitcoin edged up $5.24 or 0.55% to $959.69.
